Select Publications

Allegra CJ et al. Initial safety report of NSABP C-08, a randomized phase III study of modified 5-fluorouracil (5-FU)/leucovorin (LCV) and oxaliplatin (OX) (mFOLFOX6) with or without bevacizumab (bev) in the adjuvant treatment of patients with stage II/III colon cancer. Proc ASCO 2008;Abstract 4006.

Cassidy J et al. Surgery with curative intent in patients (pts) treated with first-line chemotherapy (CT) + bevacizumab (BEV) for metastatic colorectal cancer (mCRC): First BEAT and NO16966. Proc ASCO 2008;Abstract 4022.

Ellis LM, Haller DG. Bevacizumab beyond progression: Does this make sense? J Clin Oncol 2008;26(33):5313-5. No abstract available

Grothey A et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: Results from a large observational
cohort study (BRiTE). J Clin Oncol 2008;26(33):5326-34. Abstract

Hochster HS et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: Results of the TREE Study. J Clin Oncol 2008;26(21):3523-9. Abstract

Hurwitz HI et al. The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: Analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer. Oncologist 2009;14(1):22-8. Abstract